18 October 2021 - - US-based biotechnology company Endra Life Sciences Inc. (NASDAQ: NDRA), developer of Thermo Acoustic Enhanced UltraSound (TAEUS), has recently been issued US Patent 11147067 (the '067 patent) titled, "Method And System For Monitoring Tissue Temperature" from the United States Patent and Trademark Office, the company said.

The '067 patent relates to a novel method and system for monitoring tissue temperature during surgical procedures using Endra's TAEUS system.

Endra expects that TAEUS will be effective for both thermotherapy and cryotherapy procedures.

The recently issued patent complements US Patent 10631734, also titled, "Method And System For Monitoring Tissue Temperature," which was issued on April 28, 2020. Each of these patents utilize different methods to achieve similar results.

TAEUS is currently cleared for sale in countries that recognize the CE mark, including those in the European Union, and a 510(k) application has been submitted to the US Food and Drug Administration.

Endra Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care.

TAEUS is designed to work in concert with 400,000 cart-based ultrasound systems in use globally TODAY.

TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis, chronic liver conditions that affect over one bn people globally, and for which there are no practical diagnostic tools.

Beyond the liver, Endra is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.